AECL claims victory in dispute with Nordion over decision to kill Maple reactors

OTTAWA – Atomic Energy of Canada Ltd. is claiming victory in a long-standing battle with Nordion Inc. (TSX:NDN), an Ottawa-based nuclear medicine company.

AECL says a three-year arbitration process has ended with a majority decision in its favour.

The dispute focused on the Maple nuclear reactors that AECL decided to mothball, citing a design flaw that Nordion argued was manageable.

The twin Maple reactors had been planned as major source of isotopes used in medical imaging, once a highly profitable global business for Nordion.

However, the project was over budget and years behind schedule when AECL decided to pull the plug on the Maple reactors before they went into service.

Nordion problems got worse when AECL’s old NRU reactor was shut down for extensive repairs, cutting off the company’s main source of nuclear isotopes.

“AECL will be reviewing and analysing carefully all aspects of the decision to ensure a thorough understanding of the implications. Both AECL and Nordion are bound by confidentiality obligations relating to the arbitration process, including the details of the decision,” AECL said in its announcement Monday.

Nordion has said previously it would issue a statement before markets opened.

Its shares closed Friday at $10.46, giving Nordion a market value of about $648 million.

News from © The Canadian Press, . All rights reserved.
This material may not be published, broadcast, rewritten or redistributed.

The Canadian Press

The Canadian Press is Canada's trusted news source and leader in providing real-time, bilingual multimedia stories across print, broadcast and digital platforms.